Congestive Heart Failure (CHF) Device Market

A cardiology service line pricing a heart failure programme for 2026 starts from one number: about USD 9,380 per device, averaged across every implant and wearable it buys. The Congestive Heart Failure (CHF) Device market covers the hardware that treats or watches a failing heart: implantable cardioverter defibrillators, cardiac resynchronization therapy devices, ventricular assist pumps, implantable pulmonary artery pressure sensors and wearable defibrillators. Multiply 1.214 million units shipped in 2025 by that USD 9,380 average and the total is USD 11.39 billion, rising to USD 20.33 billion by 2035 at a revenue CAGR of 5.97%. The step change came on 13 January 2025, when Medicare issued a national coverage determination for implantable pulmonary artery pressure sensors under coverage with evidence development. Douglas Insights files this study under cardiovascular devices, and every input follows the Douglas Insights research methodology.

Why is demand for heart failure devices rising faster than the 6.7 million US patient count?

Congestive heart failure (CHF) device volume grows 4.3% a year to 2035, well ahead of patient growth. Four forces stack: ageing implant candidates, Medicare sensor coverage, wider access in Asia Pacific and more pump implants for patients who cannot get a transplant, each with a measured share of the volume leg.

The base is large and still filling. The Centers for Disease Control and Prevention puts the number of US adults with heart failure at nearly 6.7 million, and the condition appears on 14.6% of all death certificates. Douglas Insights estimates that only a minority of eligible patients with reduced ejection fraction receive a defibrillator or resynchronization device each year, so the queue alone supports steady replacement and first-implant demand. Ageing and prevalence add 1.6 points to annual unit growth, the largest single contribution.

Pressure sensors are the fastest new line. Since 13 January 2025 Medicare pays for implantable pulmonary artery pressure sensors in New York Heart Association (NYHA) class II or III patients, and on 7 February 2025 the Centers for Medicare and Medicaid Services (CMS) approved two evidence studies, one for Abbott’s CardioMEMS HF System and one for the Edwards Lifesciences Cordella PA Sensor System. Douglas Insights credits the sensor class with 1.2 points of volume growth, net of the study limits discussed below.

Access outside the West adds 0.9 points. Asia Pacific heart failure device revenue is USD 2.23 billion in 2025 and grows 8.2% a year, the fastest of any region, as more hospitals in the region add implant capacity for defibrillators and cardiac resynchronization therapy devices, a Douglas Insights assumption. Douglas Insights counts 0.9 points here, the second-largest new source of implants after sensors.

Mechanical circulatory support adds the last 0.6 points. Abbott reported heart failure sales of USD 1.45 billion for 2025, up 13.2%, a business built on the HeartMate 3 left ventricular assist device (LVAD) and the CardioMEMS sensor. The four drivers sum to 1.6 + 1.2 + 0.9 + 0.6 = 4.3 points, the full volume leg of the heart failure device model.

Replacement cycles keep the base turning. A defibrillator or CRT generator is swapped when its battery runs down, so a large share of the 1.214 million heart failure devices shipped in 2025 go to patients who already carry one. Douglas Insights models replacements at about 31% of implantable units, a share that holds steady to 2035 because first implants and replacements grow together. Fast growth in Abbott’s 13.2% heart failure line, against 6.6% for Medtronic’s wider rhythm unit, shows where the incremental dollars go: pumps and sensors, not shock boxes.

Which headwinds slow heart failure device adoption between 2026 and 2035?

Three headwinds take about 1.0 point out of heart failure device volume growth: study-only coverage for sensors, a three-month drug-therapy waiting rule and hospital price pressure in tenders. Without them the volume leg would run near 5.3% a year instead of 4.3%, and the 2035 market would sit above the base case.

Coverage with evidence development is narrow. Medicare pays for a pressure sensor only inside a CMS-approved study, only when a heart-failure-trained cardiologist manages the patient and only after a recent hospital stay or raised natriuretic peptides. Douglas Insights removes 0.4 points of sensor growth for these conditions, which keep many smaller hospitals out of the programme.

The waiting rule slows the funnel. The same coverage text requires at least 3 months of guideline-directed medical therapy, and an earlier defibrillator or resynchronization check at least 3 months before a sensor. Some patients improve on drugs and never need hardware, so Douglas Insights takes 0.3 points off device volume for that effect.

Tender pricing squeezes units as well as value. National purchasing rounds in Europe and volume-based buying in parts of Asia push hospitals to stretch device budgets across fewer high-end systems. The model removes 0.3 points of heart failure device volume for budget caps, and holds the price leg at 1.6% a year rather than the 2% to 3% list increases suppliers seek.

Which heart failure device type leads revenue: defibrillator, CRT, pump or sensor?

Implantable cardioverter defibrillators lead the congestive heart failure device market with 37.4% of 2025 revenue, USD 4.26 billion, because they serve the widest group of patients at risk of sudden death. Pressure sensors are the smallest class but grow fastest, at 14.3% a year.

Implantable cardioverter defibrillators hold USD 4.26 billion and grow 4.5% a year, slowed by a mature replacement base in the United States. Cardiac resynchronization therapy devices take 31.8%, or USD 3.62 billion, because a CRT-D combines pacing and shock therapy at a higher price per unit; Douglas Insights covers this line in more depth in its Cardiac Resynchronization Therapy (CRT) Devices Market. Ventricular assist devices earn USD 1.66 billion on a small unit count, since each pump system carries the highest price in the category. Implantable pulmonary artery pressure sensors start at USD 671.9 million and rise 14.3% a year to USD 2.56 billion, the fastest rate, because Medicare coverage arrived in 2025 and both CardioMEMS and Cordella sit in approved studies. Wearable defibrillators and other monitors add USD 1.17 billion, a rental-led line that bridges patients until a permanent implant decision.

Where do heart failure device sales grow fastest outside North America?

Asia Pacific grows fastest at 8.2% a year, from USD 2.23 billion in 2025 to USD 4.91 billion in 2035, while North America stays the largest CHF device region with USD 5.03 billion. Access schemes and a younger installed base explain the Asian lead.

North America holds 44.2% of heart failure device revenue and grows 5.05% a year, driven by sensor coverage rather than new defibrillator patients. Europe accounts for USD 3.18 billion at 5.2% a year, with tender pricing holding value growth near unit growth. Asia Pacific reaches USD 4.91 billion by 2035. Latin America adds USD 546.6 million and grows 7.0% a year from a low implant rate per head. The wildcard is the Middle East and Africa, at USD 398.5 million in 2025 but growing 7.70% a year in our model as new cardiac centres add pump programmes.

Which companies win the heart failure device business, and on what assets?

Medtronic leads with a 27.6% share of congestive heart failure device revenue, Douglas Insights estimates, and the top three suppliers hold 68.4%. Shares are modelled from disclosed segment revenue, so the leader’s figure reflects defibrillator and resynchronization sales, not the other rhythm lines in its reporting unit.

Leaders built on disclosed revenue

Medtronic reported Cardiac Rhythm and Heart Failure revenue of USD 6.39 billion for fiscal 2025, up 6.6%, in its 21 May 2025 results; the unit spans more than heart failure, so the model counts only part of it. Abbott sells the HeartMate 3 pump and the CardioMEMS sensor, and its Rhythm Management line reached USD 2.65 billion in 2025, up 10.9%. Boston Scientific supplies defibrillators and resynchronization systems inside a Cardiovascular business that reported USD 13.25 billion of 2025 net sales.

Challengers with a niche

BIOTRONIK, based in Berlin, built its position on remote Home Monitoring and the DX single-lead defibrillator; on 29 January 2024 the company reported that the 100,000th DX device had been implanted, across more than 80 countries. MicroPort CRM, based in Clamart near Paris, makes pacemakers, defibrillators and CRT systems, with plants in France, Italy, the Dominican Republic and China. Edwards Lifesciences enters through the Cordella pressure sensor, one of only 2 sensors in a Medicare-approved study after the 13 January 2025 coverage decision.

How much does a hospital pay for a CRT-D, an LVAD pump or a pressure sensor?

The CHF device average is USD 9,380 per unit in 2025, Douglas Insights calculates. Realised prices run from under USD 3,000 for a wearable rental month to above USD 80,000 for a ventricular assist pump system, so mix sets the average. List price matters less than which devices a hospital buys.

Douglas Insights price bands for 2025 hospital purchase are: single and dual-chamber defibrillators USD 14,000 to USD 22,000; CRT-D systems USD 18,000 to USD 28,000; CRT-P systems USD 6,000 to USD 9,500; pressure sensor kits USD 15,000 to USD 19,000; and LVAD systems USD 80,000 to USD 110,000. Wearable defibrillators are billed monthly, which pulls the blended unit price down. The price leg rises 1.6% a year, so the average reaches about USD 10,994 by 2035.

Which heart failure patients qualify for an implanted device rather than drugs alone?

About 1 in 5 adults with heart failure qualifies for a device in a given year, Douglas Insights reckons. Most are patients with reduced ejection fraction, NYHA class II or III symptoms and at least 3 months of drug therapy behind them. Scope here excludes pacemakers used only for slow heart rhythms.

The Medicare sensor rule spells out the gate: chronic heart failure for at least 3 months, a recent hospital stay or urgent visit, NYHA class II or III, and an earlier check for a defibrillator or resynchronization device. Pump candidates sit at the far end, in NYHA class IV, where an LVAD serves as a bridge or as destination therapy. Coverage for haemodynamic monitoring overlaps with the Cardiac Output Monitoring Device Market, which tracks non-implanted tools.

Which care settings buy heart failure devices: hospitals, clinics or surgical centres?

Hospitals buy about 81.2% of heart failure device value in 2025, because pumps, CRT-D implants and sensor procedures need cath labs and inpatient beds. Ambulatory surgical centers take 11.4% and cardiac specialty clinics 7.4%, mainly for generator replacements and wearable fitting.

Ambulatory surgical centers grow fastest among buyers, at roughly 7.9% a year in the Douglas Insights model, as payers shift simple defibrillator replacements out of hospitals. Cardiac specialty clinics run the follow-up: 1 clinic nurse often reviews remote data for several hundred implanted heart failure patients.

Why do remote monitoring links change the economics of a heart failure device?

Remote monitoring turns a one-time heart failure device sale into a service relationship worth roughly 6% of device revenue a year, Douglas Insights estimates, because pressure, rhythm and fluid data flow to clinics daily. Suppliers with the larger connected base win replacements.

BIOTRONIK built Home Monitoring around its implants, and CardioMEMS readings are taken from home through an external unit, which the Medicare rule names as part of the covered system. Data links also tie into virtual care; the Telehealth Market covers the wider software side. Douglas Insights treats this revenue as part of the device price leg, not as a separate segment.

Which rules govern heart failure device coverage after the January 2025 Medicare decision?

National coverage determination 20.36, effective 13 January 2025, is the rule that matters most for CHF devices in the United States: it pays for pressure sensors only inside approved studies. Defibrillators, CRT and pumps follow older national coverage rules.

Under the CMS coverage page, the device must be used for an FDA market-authorized indication, the patient must meet every clinical criterion, and care must happen inside a CMS-approved study. Two studies qualified on 7 February 2025, for CardioMEMS and Cordella. The rule also asks for a referring cardiologist with heart failure training and an implanting physician trained in pulmonary artery catheterization.

What if sensor uptake stalls or doubles: three heart failure device forecasts for 2035?

Our base case puts the congestive heart failure device market at USD 20.33 billion in 2035, from 4.3% volume and 1.6% price growth. The slower case ends at USD 17.07 billion and the faster case at USD 24.17 billion, with sensor coverage as the swing factor.

The slower case runs volume at 3.1% and price at 1.0%, which assumes Medicare keeps sensors inside evidence studies past 2030. The faster case runs volume at 5.6% and price at 2.1%, which assumes the 13 January 2025 coverage decision widens into routine payment. A 1-point lift in unit growth adds USD 2.04 billion to the 2035 CHF device value. Published forecasts run from about 6.4% to 10.2% a year; our 5.97% sits just below that band because the model excludes plain pacemakers.

Douglas Exclusive: the Heart Failure Device Cost-to-Coverage Matrix

The Cost-to-Coverage Matrix is a Douglas Insights model built from 15 inputs: 5 heart failure device classes scored against 3 payment settings, Medicare, European tenders and Asian public schemes. Each cell pairs the 2025 price band with how firmly that payer covers the device.

The finding: 9 of the 15 cells show full routine cover, 4 show partial or study-only cover and 2 show no routine cover. Pressure sensors score lowest, with study-only cover in Medicare and no routine cover in the 2 other settings, yet they carry the highest growth at 14.3% a year. Douglas Insights reads that gap as the main upside in the heart failure device forecast: each setting that moves a sensor to routine cover shifts the market toward the faster case.

How the model builds heart failure device revenue from units and prices?

The congestive heart failure (CHF) device model multiplies 1.214 million units by USD 9,380 to reach USD 11.39 billion in 2025, across 5 regions and 23 countries. Units grow 4.3% and price 1.6% a year, giving 5.97% revenue growth and USD 20.33 billion by 2035.

The model uses 41 data points: 6 company revenue disclosures, 2 CMS coverage records, 1 CDC prevalence figure, 5 published CAGRs and 27 price and implant-rate assumptions. Cross-check one: Medtronic, Abbott and Boston Scientific in-scope revenue sums to 68.4% of our 2025 total, inside the expected 65% to 72% band. Cross-check two: our 5.97% CAGR sits 0.43 points under the 6.4% to 10.2% published range, a gap explained by excluding pacemakers. Douglas Insights projects unit volume of 1.85 million by 2035.

Sources

1. Centers for Medicare and Medicaid Services Implantable Pulmonary Artery Pressure Sensors for Heart Failure Management (CED) (2025)
2. Centers for Medicare and Medicaid Services MLN Matters MM14000: NCD 20.36 (2025)
3. Centers for Disease Control and Prevention About Heart Failure (2025)
4. Medtronic plc / SEC Medtronic fiscal 2025 fourth quarter results (EX-99.1) (2025)
5. Abbott Abbott fourth quarter and full year 2025 results (2026)
6. Boston Scientific / SEC Boston Scientific fourth quarter and full year 2025 results (2026)
7. BIOTRONIK BIOTRONIK DX Technology reaches 100,000 devices (2024)
8. MicroPort MicroPort CRM Series C investment (2021)